(Sharecast News) - Life sciences group Abcam extended its assay and labelling capabilities on Wednesday with the acquisition of Marker Gene Technologies for an undisclosed sum.
Following Abcam's recent acquisition of Expedeon's proteomics and immunology business, the firm sought to give itself additional proprietary assay development technologies and labelling capabilities as part of its broader antibody-conjugation strategy.
The AIM-listed group said Marker Gene Technologies' team had expertise in the areas of biology, organic synthesis and fluorescence chemistry and were experienced in the creation of detection tools that enable "enhanced understanding of biological processes".
Abcam said the deal would only have a "minimal impact" on revenue and earnings in the current financial year.
As of 1025 GMT, Abcam shares were down 0.17% at 1,228.90p.
20 Jun 2023 11:18
RBC Capital Markets downgrades Abcam to 'sector perform'
(Sharecast News) - RBC Capital Markets downgraded Abcam on Tuesday to 'sector perform' from 'outperform' and cut the price target to $22 from $23 as i...
